journal article·2016-06

X-ray powder diffraction data for 5-chloro- N -(4-(5,6-dihydro-3-(4-morpholinyl)-2-oxo-1(2H)-pyridinyl)phenyl)-pentanamide, C 20 H 26 ClN 3 O 3

Qing Wang, Dan Guo, Bin Tang, Hui Li

Powder Diffraction· Volume 31· Issue 2
Publisher page

Abstract

Apixaban (Eliquis ® ) is a novel oral pyrazole-based direct FXa inhibitor. The title compound is an intermediate in the synthesis of the anticoagulant, Apixaban. X-ray powder diffraction data for the title compound, are reported [ a = 9.511(5) Å, b = 18.539(2) Å, c = 5.645(3) Å, α = 90°, β = 101.813(1)°, γ = 90°, unit-cell volume V = 974.28 Å 3 , Z = 2, ρ cal = 1.336 g cm −3 , and space group P 2]. All measured lines were indexed and are consistent with the P 2 space group. No detectable impurities were observed.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: X-ray Diffraction in Crystallography · Crystallization and Solubility Studies · Crystallography and molecular interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (8)

Show source-provided references
1. 10.2165/11209020-000000000-0000010.2165/11209020-000000000-00000 ↗
2. 10.2165/11596820-000000000-0000010.2165/11596820-000000000-00000 ↗
3. 10.1107/S002188989100644110.1107/S0021889891006441 ↗
4. 10.1107/S002188986800508X10.1107/S002188986800508X ↗
5. 10.1107/S002188987901178X10.1107/S002188987901178X ↗
6. Ye F. G. and Wang T. L. (2015). “Process for preparation of apixaban and intermediates thereof,” CN Pat., 104844593.
7. 10.1017/S088571561500072X10.1017/S088571561500072X ↗
8. 10.1107/S002188988100961810.1107/S0021889881009618 ↗